Genprex, Inc. is a clinical-stage gene therapy company focused on developing innovative treatments for cancer and diabetes. The company utilizes a proprietary technology platform to deliver cancer-fighting genes encapsulated in nanoscale hollow spheres known as nanovesicles. These nanovesicles are administered intravenously, allowing tumor cells to uptake the genes and produce essential proteins. Genprex's lead product candidate, Oncoprex immunogene therapy, targets non-small cell lung cancer (NSCLC) through a multimodal mechanism that interrupts cancer cell signaling, promotes programmed cell death, and enhances the immune response while counteracting drug resistance. The company's approach aims to meet the unmet medical needs of cancer patients by providing new therapeutic options and is designed to work synergistically with existing cancer treatments. Founded in 2009, Genprex is headquartered in Austin, Texas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.